[---] This article provides an original overview of which medical solutions to COVID-19, whether in the area of therapeutics or vaccines, will come with exclusive rights already obtained or in the process of being obtained by the life science companies developing and marketing these solutions. It will also provide, as an innovative addition to the literature, an empirical insight into how pharmaceutical companies have already obtained and will further obtain in the future, IP positions in technology necessary in the fight against COVID-19. [---]